NEW YORK, Dec. 16, 2020 /PRNewswire/ — atai Daily life Sciences (“atai” or the “Company”), a global biotech enterprise developing psychedelic and non-psychedelic compounds for numerous mental wellness indications, has announced the appointment of Greg Weaver as Chief Monetary Officer (CFO) and Rolando Gutierrez-Esteinou as Chief Clinical Officer (CMO).
Mr. Weaver joins atai with in depth expertise in finance, getting held several government positions in the area of biotechnology. Greg’s career has targeted on start off-up via scientific growth and professional phase. He has guided around $1.1 billion in funding transactions for the duration of his vocation, participated in numerous public and private financings, offering financial guidance, strategic management and shareholder benefit. Prior to becoming a member of atai, Mr. Weaver was CFO at various productive providers, together with SIRNA Therapeutics, ILEX Oncology, Oryzon, Prometic, and Eloxx Prescription drugs.
“Greg brings a prosperity of practical experience with a demonstrated observe file in sophisticated economic corporations, the place he was liable for a selection of companies’ effective general public offerings,” stated atai CEO and Co-Founder Florian Brand name. “As we continue on to increase and evolve, Greg’s deep financial knowledge and know-how will be invaluable.”
Mr. Weaver retains a BS in accounting and finance from Trinity University and an MBA from Boston College’s Wallace E. Carroll Graduate College of Management.
“I am thrilled to be part of atai at this incredibly thrilling time, and to have the opportunity to serve with this extraordinary team,” explained Mr. Weaver. “It is obvious that atai has a distinctive and persuasive society of innovation, empathy, and producing a sizeable impact on behalf of psychological health and fitness people. I glimpse forward to driving our shared eyesight of leaving no individual behind.”
Dr. Gutierrez-Esteinou is a seasoned pharmaceutical executive in neuroscience drug development and commercialization. Having grow to be a psychiatrist some 30 decades back, Rolando was about in the course of the breakthroughs of serotonin selective reuptake inhibitors (SSRIs) and atypical antipsychotics, some of which he assisted establish.
In the course of this time, he has held govt positions at earth-renowned companies which includes Johnson & Johnson, Novartis, BMS, Takeda and Marinus in medical advancement, task administration, health care affairs and pharmacovigilance.
“Rolando’s 3 decades of expertise in the neuroscience space and his legitimate comprehending of the potential of these compounds speaks immediately to our values at atai,” reported Dr. Srinivas Rao, atai Co-Founder and Main Scientific Officer. “His depth of information and practical experience in CNS drug enhancement will add considerably in our efforts to transfer our portfolio forward.”
Dr. Gutierrez-Esteinou received his MD from the Universidad Nacional Autonoma de Mexico, and did his subsequent residency in the division of psychiatry as perfectly as his fellowship in the section of neurochemistry at Harvard Professional medical College. Moreover, he concluded his fellowship in experimental therapeutics at the National Institute of Psychological Overall health (NIMH).
“I am quite fired up to be part of atai at a time when the development of psychedelics is progressing into later phases of clinical screening in several psychiatric problems of high unmet need to have,” claimed Dr. Gutierrez-Esteinou. “The exclusive therapeutic effects of these investigational medicinal products will require innovation in the way reports are conceived, made, applied and analyzed so atai has assembled the group of professionals who can deal with these responsibilities.”
Dr. Gutierrez-Esteinou will be centered in New Jersey and Mr. Weaver will be based in New York City.
About atai Lifetime Sciences
atai is a biotechnology organization established in 2018 in response to the very clear and expanding unmet demands of mental wellness clients throughout the world. atai is committed to getting, incubating and competently establishing ground breaking therapeutics to treat despair, stress, addiction, and other mental health and fitness diseases. atai’s small business model combines funding, technological know-how, scientific and regulatory expertise with a emphasis on psychedelic therapy and other medicines with differentiated security profiles and therapeutic possible. By pooling resources and very best techniques, atai aims to responsibly accelerate the growth of new medications across its company entities, trying to find to effectively address and in the long run heal mental wellness problems. atai’s mission is to bridge the hole between what the mental healthcare procedure presently delivers and what sufferers need. atai is headquartered in Berlin, with workplaces in New York and San Diego. For far more information, please pay a visit to www.atai.daily life.
Investor Make contact with:
atai – Chief Fiscal Officer
Email: [email protected]
Media Get hold of:
KCSA Strategic Communications
Cell phone: +1 (212) 896-1265
Email: [email protected]
Resource atai Existence Sciences